• BeyondSpring is laying off 35% of staff in wake of FDA rejection of lead drug

    9 days ago - By MedCity News

    BeyondSpring Pharmaceuticals' corporate reorganization comes about six weeks after the FDA rejected the biotech's drug for a complication experienced by cancer patients. The company still plans to develop the drug for that application and others, but it added that layoffs are needed to reduce expenses.
    Read more ...